Abstract
The identification of novel molecular targets has paved the way for new treatment options in cancer patients. A number of agents targeting molecules that are crucial both for the tumor and its microenvironment have already been approved by the U.S. Food and Drug Administration for clinical use. The monoclonal antibodies and the small molecule kinase inhibitors constitute two major classes of targeted therapeutic agents, which have apparently different mechanisms of action, toxicity profiles, routes of administration, timing and dosing. Moreover, individual differences in genes regulating the distribution and metabolism of targeted agents evidently influence treatment outcomes. Data regarding the immune- and tumor microenvironment-modulatory properties of most of these agents are either obscure or controversial, as well. Therefore, preclinical animal and human studies that aim to identify the immunological, biological and the pharmacological properties of these novel classes of agents that also employ recent developments in pharmacogenomics and proteomics are warranted.
Keywords: Targeted therapy, targeted therapeutic agents, small molecule kinase inhibitors, therapeutic monoclonal antibodies, anti-tumor immune responses, angiogenesis, EGF, VEGF, sorafenib, sunitinib.
Protein & Peptide Letters
Title:Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Volume: 20 Issue: 12
Author(s): S. Altug Kesikli and Saadettin Kilickap
Affiliation:
Keywords: Targeted therapy, targeted therapeutic agents, small molecule kinase inhibitors, therapeutic monoclonal antibodies, anti-tumor immune responses, angiogenesis, EGF, VEGF, sorafenib, sunitinib.
Abstract: The identification of novel molecular targets has paved the way for new treatment options in cancer patients. A number of agents targeting molecules that are crucial both for the tumor and its microenvironment have already been approved by the U.S. Food and Drug Administration for clinical use. The monoclonal antibodies and the small molecule kinase inhibitors constitute two major classes of targeted therapeutic agents, which have apparently different mechanisms of action, toxicity profiles, routes of administration, timing and dosing. Moreover, individual differences in genes regulating the distribution and metabolism of targeted agents evidently influence treatment outcomes. Data regarding the immune- and tumor microenvironment-modulatory properties of most of these agents are either obscure or controversial, as well. Therefore, preclinical animal and human studies that aim to identify the immunological, biological and the pharmacological properties of these novel classes of agents that also employ recent developments in pharmacogenomics and proteomics are warranted.
Export Options
About this article
Cite this article as:
Kesikli Altug S. and Kilickap Saadettin, Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients, Protein & Peptide Letters 2013; 20 (12) . https://dx.doi.org/10.2174/092986652012131112123040
DOI https://dx.doi.org/10.2174/092986652012131112123040 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects
Current Pharmaceutical Biotechnology A Survey on Machine Learning Based Medical Assistive Systems in Current Oncological Sciences
Current Medical Imaging FDG-PET Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica: A Personal View
Current Immunology Reviews (Discontinued) Downregulation of CCKBR Expression Inhibits the Proliferation of Gastric Cancer Cells, Revealing a Potential Target for Immunotoxin Therapy
Current Cancer Drug Targets Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Current Medicinal Chemistry Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review
Current Drug Delivery Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics